FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-09

Price

$14.37

+0.21%

Score7.0Priority

Signals4/8 DNA3/13 Act · 0/4 Risk

SentimentNEUTRALScore: 0

Volume0.7xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is currently trading at $14.37, tightly pinned just below its $14.50 all-cash acquisition price by BioMarin Pharmaceutical. The algorithmic technical signals (ALPHA_MALE, QUIET_STORM) are triggering as an artifact of this merger arbitrage, misinterpreting the artificially low 2.1% realized volatility as organic accumulation. With Amicus stockholders officially approving the buyout on March 3, 2026, the stock is completely insulated from the broader NEUTRAL macro regime and completely ignored a recent February earnings miss. FOLD is no longer trading on fundamentals but is functioning strictly as a yield instrument capturing the final $0.13 spread ahead of the expected Q2 2026 close.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSPERFECT STACKSELLER FATIGUESMA BOUNCEINSIDE OUT

Key Takeaways

Actionable Thesis: FOLD is a pure merger arbitrage play offering a capped ~0.9% gross spread to the $14.50 BioMarin buyout price, making it a defensive hold rather than a directional breakout candidate.
Key Risk: The primary downside risk is regulatory or antitrust intervention (FTC/HSR clearance) that could block or delay the deal before its targeted Q2 2026 close.
What to Watch: Monitor regulatory dockets for antitrust clearance updates, as shareholder approval has already been secured.

← Back to 2026-03-09 View Full FOLD History →Yahoo Finance &nearr;